<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36988251</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy.</ArticleTitle><Pagination><StartPage>e815</StartPage><MedlinePgn>e815</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e815</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.815</ELocationID><Abstract><AbstractText>Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). The chronic graft versus host disease (cGVHD) mouse model is a well-established model of SLE. LC3-associated autophagy plays a critical role in extracellular particle clearance, including pathogens and apoptotic cells. Lupus Recipe (LR) is a Chinese herbal compound that has been proven to be effective in treating SLE. In the study, we investigated the protective effects of LR or LR combined with prednisone on cGVHD mouse model and LC3-associated autophagy in the kidney. The mice were subjected to six groups. The LR treatment group received LR at the dosage of 1.15 and 2.3&#x2009;g/kg/day, respectively. The corticosteroid treatment group received prednisone at a dosage of 5&#x2009;mg/kg/day. The combination treatment group received LR at a dosage of 2.3&#x2009;g/kg/day, and prednisone at 2.5&#x2009;mg/kg/day. LR treatment reduced proteinuria and serum triglyceride levels, as well as spleen weight. LR also alleviated pathologic damage and immunoglobulin G deposition in the kidney. LR combined with a low dose of prednisone significantly improved kidney function and decreased serum triglyceride, total cholesterol, and spleen weight. In addition, combination treatment relieved kidney injury more effectively than LR alone. Western blot revealed that LR treatment or LR combined with prednisone increased the LC3-associated autophagy protein of Rubicon and Nox2, as well as LC3I levels in the kidney tissues. In conclusion, LR inhibited the manifestation of cGVHD-induced LN, which may attribute to the increased levels of LC3-associated autophagy.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ruihua</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Hongjian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Haishan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Meiju</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jinjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-0437-2015</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092122" MajorTopicYN="Y">Bronchiolitis Obliterans Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The author declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>8</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36988251</ArticleId><ArticleId IdType="pmc">PMC10022419</ArticleId><ArticleId IdType="doi">10.1002/iid3.815</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. 2020;76:265&#x2010;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Pitsigavdaki S, Bertsias G. Lupus nephritis: improving treatment options. Drugs. 2022;82:735&#x2010;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">35486369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz&#x2010;Arruza I, Barbosa C, Ugarte A, Ruiz&#x2010;Irastorza G. Comparison of high versus low&#x2010;medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14:875&#x2010;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">26044819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz&#x2010;Arruza I, Ugarte A, Cabezas&#x2010;Rodriguez I, Medina JA, Moran MA, Ruiz&#x2010;Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology. 2014;53:1470&#x2010;1476.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Mompean E, Radin M, Roccatello D, Cuadrado MJ. Rate of adverse effects of medium&#x2010; to high&#x2010;dose glucocorticoid therapy in systemic lupus erythematosus: A systematic review of randomized control trials. Clin Drug Invest. 2017;37:519&#x2010;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">28357813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KP, Zhang ZH, Li RM, Chen X. The therapeutic effects of the Chinese herbal Medicine, lang chuang fang granule, on Lupus&#x2010;Prone MRL/lpr mice. Evid Based Comple Alter Med. 2016;2016:1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789466</ArticleId><ArticleId IdType="pubmed">27034698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Ye R, Pei C, et al. Observational study of lang chuang fang and immunosuppressants in the treatment of lupus nephritis. Chinese J Medicine. 2000;35:45&#x2010;46.</Citation></Reference><Reference><Citation>Li Y, Yang X, Wei Y, et al. Ameliorate chemokine RANTES expression by the recipe of LangChangFang in murine lupus nephritis model. Chinese J Immunol. 2002;18:631&#x2010;635.</Citation></Reference><Reference><Citation>Li Y, Yang X, Wei Y, et al. Effect of lupus recipe on IL&#x2010;6 and IL&#x2010;10 secretion of splenic cells in vitro in lupoid mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002;22:369&#x2010;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584841</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang M, Li Y, Yang X, et al. Influence of recipe of lang chang fang on serum IL&#x2010;6 and IL&#x2010;10 in lupus mice. Chinese J Integr Traditi Western Nephrol. 2001;2:502&#x2010;504.</Citation></Reference><Reference><Citation>Zhang Y, Yang X, Chen W, et al. Effect of lupus recipe contained serum on the expression of PPAR&#x3b3; and TNF&#x3b1; with IFN&#x3b3; induced CD40 and RANTES on renal tubular epithelial cells. Chinese J Experi Tradit Med Formulae. 2008;14:30&#x2010;34.</Citation></Reference><Reference><Citation>Heckmann BL, Green DR. LC3&#x2010;associated phagocytosis at a glance. J Cell Sci. 2019;132:jcs222984. 10.1242/jcs231472</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs231472</ArticleId><ArticleId IdType="pmc">PMC6432721</ArticleId><ArticleId IdType="pubmed">30787029</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez J, Cunha LD, Park S, et al. Retracted article: noncanonical autophagy inhibits the autoinflammatory, lupus&#x2010;like response to dying cells. Nature. 2016;533:115&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860026</ArticleId><ArticleId IdType="pubmed">27096368</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann BL, Boada&#x2010;Romero E, Cunha LD, Magne J, Green DR. LC3&#x2010;Associated phagocytosis and inflammation. J Mol Biol. 2017;429:3561&#x2010;3576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743439</ArticleId><ArticleId IdType="pubmed">28847720</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Q, Li Y, Li J, et al. WDFY4 is involved in symptoms of systemic lupus erythematosus by modulating B cell fate via noncanonical autophagy. J Immunol. 2018;201:2570&#x2010;2578.</Citation><ArticleIdList><ArticleId IdType="pubmed">30257884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ouyang X, Xu Z, et al. CD8+CD103+ iTregs inhibit chronic Graft&#x2010;versus&#x2010;Host disease with lupus nephritis by the increased expression of CD39. Mol Ther. 2019;27:1963&#x2010;1973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838901</ArticleId><ArticleId IdType="pubmed">31402273</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689&#x2010;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Titov AA, Morel L. An update on lupus animal models. Curr Opin Rheumatol. 2017;29:434&#x2010;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815391</ArticleId><ArticleId IdType="pubmed">28537986</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg RA, Via CS. T cells, murine chronic graft&#x2010;versus&#x2010;host disease and autoimmunity. J Autoimmun. 2012;39:240&#x2010;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578438</ArticleId><ArticleId IdType="pubmed">22704961</ArticleId></ArticleIdList></Reference><Reference><Citation>University HKB. Medicinal Plant Images Database [Z]. Accessed September 21, 2021.</Citation></Reference><Reference><Citation>Hung HY, Cheng KC, Kuo PC, et al. Chemical constituents of hedyotis diffusa and their anti&#x2010;inflammatory bioactivities. Antioxidants. 2022;11:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8868389</ArticleId><ArticleId IdType="pubmed">35204218</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y, Ji J, Li Y, et al. Ethyl acetate fraction in hedyotis diffusa willd inhibits T cell proliferation to improve the pathogenesis of systemic lupus erythematosus. Clin Comple Med Pharmacol. 2021;1:100011.</Citation></Reference><Reference><Citation>Ji L, Hou X, Deng X, et al. Jieduquyuziyin Prescription&#x2010;Treated rat serum suppresses activation of peritoneal macrophages in MRL/Lpr lupus mice by inhibiting IRAK1 signaling pathway. Evid Based Complemen Altern Med. 2019;2019:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6875022</ArticleId><ArticleId IdType="pubmed">31781262</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Chen F, Zhang L, et al. Exploring the mechanisms of anti&#x2010;ovarian cancer of hedyotis diffusa willd and scutellaria barbata D. Don through focal adhesion pathway. J Ethnopharmacol. 2021;279:114343.</Citation><ArticleIdList><ArticleId IdType="pubmed">34147618</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Li H, Zhang M, et al. Quercitrin ameliorates the development of systemic lupus erythematosus&#x2010;like disease in a chronic graft&#x2010;versus&#x2010;host murine model. Am J Physiology&#x2010;Renal Physiology. 2016;311:F217&#x2010;F226.</Citation><ArticleIdList><ArticleId IdType="pubmed">26911849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Santos M, Poletti PT, Favero G, et al. Protective effects of quercetin treatment in a pristane&#x2010;induced mouse model of lupus nephritis. Autoimmunity. 2018;51:69&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29480020</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Shi G, Wang J, et al. Baicalein ameliorates pristane&#x2010;induced lupus nephritis via activating Nrf2/HO&#x2010;1 in myeloid&#x2010;derived suppressor cells. Arthritis Res Ther. 2019;21:105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482536</ArticleId><ArticleId IdType="pubmed">31023362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen BL, Wang LT, Huang KH, Wang CC, Chiang CK, Liu SH. Quercetin attenuates renal ischemia/reperfusion injury via an activation of AMP&#x2010;activated protein kinase&#x2010;regulated autophagy pathway. J Nutr Biochem. 2014;25:1226&#x2010;1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">25087994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz&#x2010;Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145&#x2010;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">22271756</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>